Emyria Ltd. is a healthcare technology and services company. The company is headquartered in Leederville, Western Australia. The company went IPO on 2020-02-12. The firm is focused on delivering and developing treatments for mental health and select neurological conditions, guided by real-world data collected with patients across its wholly owned clinical service subsidiaries. Its pipeline comprises MDMA analogue drug development and commercialization of novel serotonin-releasing agents. Its Emyria Healthcare provides evidence-based treatment for patients not finding relief from conventional care, while also helping evaluate emerging new therapies like assisted therapy for post-traumatic stress disorder (PTSD) and assisted therapy for treatment-resistant depression. Its Emyria Data is a robust and ethically sourced real-world data gathered with patients and used to improve its therapy and drug development programs. Its Emyria’s Pipeline includes new psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.
Follow-Up Questions
EMYRF hissesinin fiyat performansı nasıl?
EMYRF 'in mevcut fiyatı $0 'dir, son işlem günde 0% decreased etti.
Emyria Ltd için ana iş temaları veya sektörler nelerdir?
Emyria Ltd Pharmaceuticals endüstrisine ait ve sektör Health Care 'dir
Emyria Ltd 'in piyasa değerlemesi nedir?
Emyria Ltd 'in mevcut piyasa değerlemesi $NaN 'dir
